Trial
NCT03458728
Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Bayer
Collaborators
—
Condition
Relapsed or Refractory Solid Tumors or Lymphoma in Children
Intervention
Copanlisib (BAY806946)
Why stopped
no anticipated benefit over available standard therapies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-12-04